A$11.99
1.52% today
Australia, Oct 16, 07:10 am CET
ISIN
AU000000CUV3
Symbol
CUV

Clinuvel Pharmaceutical Stock price

A$11.99
+0.75 6.67% 1M
+1.34 12.60% 6M
-0.01 0.10% YTD
-2.05 14.61% 1Y
-5.32 30.74% 3Y
-10.34 46.32% 5Y
+9.24 335.49% 10Y
+8.51 244.47% 20Y
Australia, Closing price Thu, Oct 16 2025
+0.18 1.52%
ISIN
AU000000CUV3
Symbol
CUV
Industry

Key metrics

Basic
Market capitalization
A$605.9m
Enterprise Value
A$382.3m
Net debt
positive
Cash
A$224.1m
Shares outstanding
50.1m
Valuation (TTM | estimate)
P/E
16.4 | 15.5
P/S
6.4 | 5.8
EV/Sales
4.0 | 3.7
EV/FCF
9.4
P/B
2.5
Dividends
DPS
A$0.05
Yield 1Y | 5Y
0.4% | 0.2%
Growth 1Y | 5Y
0.0% | 14.9%
Payout 1Y | 3Y
6.9% | 7.5%
Increased
0 Years
Financials (TTM | estimate)
Revenue
A$95.0m | A$103.8m
EBITDA
A$46.9m | A$45.7m
EBIT
A$45.7m | A$44.4m
Net Income
A$36.2m | A$38.1m
Free Cash Flow
A$40.8m
Growth (TTM | estimate)
Revenue
-0.5% | 9.2%
EBITDA
-18.1% | -2.7%
EBIT
-18.5% | -2.8%
Net Income
1.5% | 5.3%
Free Cash Flow
29.6%
Margin (TTM | estimate)
Gross
98.1%
EBITDA
49.4% | 44.0%
EBIT
48.1%
Net
38.1% | 36.7%
Free Cash Flow
42.9%
Financial Health
Equity Ratio
88.6%
Return on Equity
15.0%
ROCE
18.7%
ROIC
153.8%
Debt/Equity
0.0
More
EPS
A$0.7
FCF per Share
A$0.8
Short interest
-
Employees
16
Rev per Employee
A$5.9m
Show more

Is Clinuvel Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Clinuvel Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Clinuvel Pharmaceutical forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Clinuvel Pharmaceutical forecast:

Buy
80%
Hold
20%

Financial data from Clinuvel Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
95 95
1% 1%
100%
- Direct Costs 1.81 1.81
263% 263%
2%
93 93
4% 4%
98%
- Selling and Administrative Expenses 39 39
3% 3%
41%
- Research and Development Expense 7.40 7.40
215% 215%
8%
47 47
18% 18%
49%
- Depreciation and Amortization 1.18 1.18
4% 4%
1%
EBIT (Operating Income) EBIT 46 46
18% 18%
48%
Net Profit 36 36
1% 1%
38%

In millions AUD.

Don't miss a Thing! We will send you all news about Clinuvel Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Lachlan Hay
Employees 16
Founded 1999
Website www.clinuvel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today